Profile data is unavailable for this security.
About the company
Maat Pharma SA is a France-based company, which is engaged into research and development in biotechnology sector. The Company specializes in the microbiome therapy that is aimed to treatment of Gut Microbiota alteration (Dysbiosis) using patient-specific biotherapeutics in patients with serious medical conditions. Its MaaT Microbiome Restoration Therapy (MMRB) discovery and analysis platform supports the evaluation of drug candidates, the determination of new disease targets and the identification of biomarkers for microbiome-related conditions.
- Revenue in EUR (TTM)2.57m
- Net income in EUR-24.14m
- Incorporated2014
- Employees50.00
- LocationMaat Pharma SA70 Avenue Tony GarnierLYON 69007FranceFRA
- Phone+33 428291400
- Websitehttps://www.maatpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nfl Biosciences SAS | 0.00 | -2.37m | 22.32m | 4.00 | -- | 6.42 | -- | -- | -0.2653 | -0.2653 | 0.00 | 0.3584 | 0.00 | -- | -- | 0.00 | -44.70 | -83.27 | -70.88 | -122.37 | -- | -- | -- | -- | -- | -- | 0.0151 | -- | -- | -- | -53.28 | -- | -- | -- |
| Oncodesign Precision Medicine Opm SA | 468.73k | -7.78m | 23.65m | 19.00 | -- | 7.50 | -- | 50.45 | -0.449 | -0.449 | 0.0269 | 0.1733 | 0.0311 | -- | 0.4553 | 21,305.91 | -51.68 | -- | -85.27 | -- | 153.18 | -- | -1,660.23 | -- | -- | -360.87 | 0.715 | -- | -86.57 | -- | -3,399.73 | -- | -- | -- |
| Fermentalg SA | 8.04m | -14.14m | 33.17m | 62.00 | -- | 0.5041 | -- | 4.13 | -0.2836 | -0.2836 | 0.1564 | 0.7637 | 0.1395 | 1.34 | 4.82 | 129,629.00 | -22.80 | -21.94 | -25.70 | -24.71 | 14.04 | 14.73 | -163.46 | -248.95 | 3.42 | -53.73 | 0.2639 | -- | -46.94 | 75.18 | -43.29 | -- | -10.93 | -- |
| genOway SA | 20.05m | 1.57m | 34.22m | 133.00 | 20.71 | 1.97 | 8.53 | 1.71 | 0.1782 | 0.1782 | 2.28 | 1.88 | 0.619 | 0.773 | 3.10 | 150,724.70 | 4.84 | 0.2166 | 6.64 | 0.3048 | 95.82 | 94.82 | 7.82 | 0.4177 | 1.95 | 28.11 | 0.3047 | -- | 17.55 | 13.16 | 101.55 | 22.35 | -- | -- |
| Gensight Biologics SA | 804.00k | -20.11m | 40.81m | 11.00 | -- | -- | -- | 50.76 | -0.3537 | -0.3537 | 0.0123 | -0.2402 | 0.0507 | -- | 21.73 | 50,250.00 | -126.79 | -79.44 | -- | -144.54 | -- | -- | -2,501.00 | -1,036.27 | -- | -1,250.38 | -- | -- | -50.93 | -- | 5.09 | -- | -58.28 | -- |
| Abionyx Pharma SA | 4.86m | -3.36m | 43.52m | 61.00 | -- | 4.25 | -- | 8.96 | -0.1063 | -0.1063 | 0.1548 | 0.2934 | 0.3316 | 21.80 | 6.05 | 80,264.46 | -22.93 | -18.82 | -33.15 | -28.87 | 19.19 | 14.32 | -69.15 | -128.54 | 2.22 | -114.07 | 0.2513 | -- | -11.65 | 92.84 | 16.36 | -- | 41.40 | -- |
| Novacyt SA | 22.15m | -44.59m | 49.00m | 240.00 | -- | 0.5825 | -- | 2.21 | -0.6313 | -0.6361 | 0.3137 | 1.19 | 0.1603 | -3.66 | 1.02 | 82,046.80 | -32.27 | 10.94 | -38.44 | 14.49 | 153.78 | 61.98 | -201.27 | 17.64 | 3.82 | -159.39 | 0.1573 | -- | -44.97 | -0.9408 | -25.22 | -- | 2.09 | -- |
| Inventiva SA | 15.62m | -104.19m | 76.93m | 112.00 | -- | -- | -- | 4.93 | -2.08 | -2.08 | 0.3104 | -- | -- | -- | -- | 139,437.50 | -- | -54.30 | -- | -69.98 | -- | -- | -653.15 | -669.97 | -- | -- | -- | -- | 43.50 | 40.46 | -103.46 | -- | -0.33 | -- |
| Adocia SA | 2.15m | -21.16m | 81.11m | 78.00 | -- | -- | -- | 37.73 | -1.93 | -1.93 | 0.194 | -0.4908 | 0.0774 | 2.62 | 7.44 | 27,564.10 | -76.16 | -43.08 | -396.14 | -72.93 | 7.91 | -- | -984.28 | -514.53 | 1.01 | -2.07 | 2.12 | -- | -81.22 | -46.13 | -206.65 | -- | -27.60 | -- |
| Maat Pharma SA | 2.57m | -24.14m | 102.44m | 50.00 | -- | 4.00 | -- | 39.84 | -2.03 | -2.03 | 0.2161 | 1.84 | 0.0511 | 6.50 | 2.18 | 51,420.00 | -47.94 | -35.49 | -64.64 | -42.98 | 67.87 | -- | -938.86 | -1,157.54 | 2.75 | -47.95 | 0.4014 | -- | 55.80 | -- | -43.78 | -- | 30.30 | -- |
| Eurofins-Cerep SA | 42.42m | 7.25m | 109.96m | 218.00 | 15.16 | 1.63 | 11.89 | 2.59 | 1,438.10 | 1,438.10 | 8,415.76 | 13,378.57 | 0.5618 | 1.52 | 5.41 | 186,032.70 | 9.61 | 14.21 | 11.08 | 17.51 | 85.48 | 73.61 | 17.10 | 19.77 | 6.89 | -- | 0.0047 | -- | -7.47 | 11.60 | -33.72 | 14.64 | -- | -- |
| Cellectis SA | 17.88m | -89.93m | 133.73m | 235.00 | -- | 0.9834 | -- | 7.48 | -1.41 | -1.13 | 0.2384 | 1.89 | 0.0619 | -- | 3.86 | 76,096.07 | -31.74 | -24.08 | -46.51 | -30.69 | -- | -64.64 | -513.02 | -308.24 | -- | -6.95 | 0.4142 | -- | -64.26 | -15.57 | -20.55 | -- | -26.15 | -- |
Data as of Oct 09 2024. Currency figures normalised to Maat Pharma SA's reporting currency: Euro EUR
0.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Financi�re Arbevel SAas of 30 Dec 2022 | 20.00k | 0.14% |
| Simplify Asset Management, Inc.as of 05 Jul 2024 | 1.36k | 0.01% |
Data from 31 Mar 2024 - 28 Jun 2024Source: FactSet Research Systems Inc.
